Ignite Creation Date:
2024-05-05 @ 11:59 AM
Last Modification Date:
2024-10-26 @ 9:17 AM
Study NCT ID:
NCT00193440
Status:
COMPLETED
Last Update Posted:
2010-12-30
First Post:
2005-09-12
Brief Title:
Rituximab and Chemotherapy Followed by Ibritumomab Tiuxetan as Treatment for Low Grade Follicular Non-Hodgkins Lymphoma
Sponsor:
SCRI Development Innovations LLC
Organization:
SCRI Development Innovations LLC
Study Overview
Official Title:
Phase II Trial of Rituximab and Short Duration Chemotherapy Followed by Zevalin as First-Line Treatment for Patients With Low Grade Follicular Non-Hodgkins Lymphoma
Status:
COMPLETED
Status Verified Date:
2010-12
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
In this trial we will evaluate the feasibility toxicity and effectiveness ibritumomab tiuxetan when incorporated into combination first-line treatment for follicular lymphoma Addition of the ibritumomab tiuxetan to our previously evaluated well tolerated combination of rituximab and short course chemotherapy will allow the use of additional active agent with a unique mechanism of cytotoxicity In addition debulking of lymphoma prior to 90Y Zevalin administration may minimize the myelotoxicity of this agent
Detailed Description:
Upon determination of eligibility patients will be receive
Rituxan CHOP or CVP Ibritumomab Tiuxetan
Patients who are considered medical candidates for doxorubicin should receive CHOP chemotherapy Cyclophosphamide doxorubicin vincristine and prednisone Patients who are not considered medical candidates for doxorubicin should receive CVP chemotherapy Cyclophosphamide Vincristine and prednisone
Rituxan CHOP or CVP Ibritumomab Tiuxetan
Patients who are considered medical candidates for doxorubicin should receive CHOP chemotherapy Cyclophosphamide doxorubicin vincristine and prednisone Patients who are not considered medical candidates for doxorubicin should receive CVP chemotherapy Cyclophosphamide Vincristine and prednisone
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| 106-PO69 | None | None | None |